Alpha Tau Medical Ltd Cl A (DRTS) Stock Price, Quote & News

Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 3 577 4115

Website: www.alphatau.com

Address:

Kiryat HaMada St. 5, Jerusalem, Israel

DJTEM Aug. 24 at 7:45 AM

$DRTS At least. Goldie

0 · Reply

Stock_Catcher Aug. 24 at 12:25 AM

Money Monday Watchlist - Daily Expansion $CLOV $RUM $HIVE $HYLN $DRTS

1 · Reply

Jordan3333 Aug. 23 at 10:32 AM

$DRTS Now that we got to $15 the Keytruda IDE announcement can get us beyond the $18, and with the warrant exercise, the price should double

3 · Reply

Jessypenny Aug. 23 at 10:00 AM

$DRTS Getting used to posting this: Another ATH at $15.02 and another highest close at $14.92. Momentum keeps building and I'm Extremely bullish as ever.

0 · Reply

JohnStocksNY Aug. 23 at 7:42 AM

$DRTS I think about Alpha Tau every day.

2 · Reply

Dutchholdem Aug. 22 at 8:10 AM

$DRTS Alpha Tau Medical (DRTS) officer schedules next stock sale under 10b5-1 plan. Yesterday 5k shares at 14.38 approximately it seems as part of predefined plan.

2 · Reply

Watchingnow Aug. 21 at 10:59 PM

$DRTS sold $15 puts expiring today. At 4pm closed below. Hope i get assigned.

0 · Reply

Matilda_CS Aug. 21 at 7:35 PM

$DRTS 15 has been a massive resistance the last few weeks. But we’re getting closer, and closer. Hopefully soon we’ll be looking back at 15 as a “remember when they were at 15? Great days!” scenario

2 · Reply

Dutchholdem Aug. 21 at 7:25 PM

$DRTS Raphi auto option executing again like at 14 dollar, or profit takers at 15? I am fine either way, not planning to sell anything

2 · Reply

Matilda_CS Aug. 21 at 6:41 PM

$DRTS with a little push, we could clear 15 by code

2 · Reply

Alpha Tau price target raised to $16 from $15 at H.C. Wainwright

2026-08-10T20:20:38.000Z - 13 days ago

Alpha Tau reports Q2 EPS (25c), consensus (14c)

Aug 10, 2026, 8:00 AM EDT - 13 days ago

Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)

2026-07-21T13:05:21.000Z - 4 weeks ago

Alpha Tau reports Alpha DaRT combination study results

Jul 21, 2026, 8:30 AM EDT - 4 weeks ago

Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success

2026-07-15T13:15:30.000Z - 5 weeks ago

Alpha Tau treats first patient in ADMIRE study for recurrent skin cancer

Jul 15, 2026, 8:30 AM EDT - 5 weeks ago

Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center

2026-06-23T16:01:28.000Z - 2 months ago

Alpha Tau treats first glioblastoma patient in Israel with Alpha DaRT

Jun 23, 2026, 8:30 AM EDT - 2 months ago

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel

2026-06-11T13:17:41.000Z - 2 months ago

Alpha Tau gets FDA clearance to complete enrollment in REGAIN trial

Jun 11, 2026, 8:30 AM EDT - 2 months ago

Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control

2026-06-04T09:11:16.000Z - 2 months ago

Alpha Tau price target raised to $17 from $15 at Barclays

2026-06-03T14:53:02.000Z - 2 months ago

Alpha Tau, Tolmar announce strategic collaboration agreement

Jun 3, 2026, 8:30 AM EDT - 2 months ago

Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients

2026-06-01T13:43:39.000Z - 2 months ago

Alpha Tau reports positive survival data from pancreatic cancer study

Jun 1, 2026, 9:00 AM EDT - 2 months ago

Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting

May 28, 2026, 9:00 AM EDT - 3 months ago

Alpha Tau Medical Transcript: Lytham Partners Spring 2026 Investor Conference

2026-05-28T09:27:08.000Z - 3 months ago

Alpha Tau initiated with an Overweight at Barclays

2026-05-19T11:07:23.000Z - 3 months ago

Alpha Tau price target raised to $8 from $5 at Piper Sandler

2026-05-18T20:08:09.000Z - 3 months ago

Alpha Tau reports Q1 EPS (12c), consensus (12c)

May 18, 2026, 4:01 PM EDT - 3 months ago

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

May 18, 2026, 4:00 PM EDT - 3 months ago

Alpha Tau Medical Earnings release: Q1 2026

May 18, 2026, 8:30 AM EDT - 3 months ago

Alpha Tau to Participate in May Investor Conferences

May 15, 2026, 7:00 AM EDT - 3 months ago

Alpha Tau Medical Slides: Investor presentation

2026-05-12T15:35:38.000Z - 3 months ago

Alpha Tau price target raised to $14 from $12 at Ladenburg

2026-05-12T10:48:07.000Z - 3 months ago

Alpha Tau price target raised to $15 from $12 at H.C. Wainwright

May 11, 2026, 8:30 AM EDT - 3 months ago

Alpha Tau Medical Transcript: Study result

May 11, 2026, 8:30 AM EDT - 3 months ago

Alpha Tau Medical Press release: Study result

May 11, 2026, 8:30 AM EDT - 3 months ago

Alpha Tau Medical Slides: Study result

2026-05-11T12:24:42.000Z - 3 months ago

Alpha Tau announces interim data from REGAIN trial

May 11, 2026, 7:00 AM EDT - 3 months ago

Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET

2026-05-08T15:18:00.000Z - 3 months ago

Alpha Tau completes enrollment in ReSTART trial

May 8, 2026, 9:10 AM EDT - 3 months ago

Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma

May 8, 2026, 9:00 AM EDT - 3 months ago

Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma

2026-05-07T18:29:44.000Z - 3 months ago

Alpha Tau treats first patient with Alpha DaRT in Italy

May 7, 2026, 9:00 AM EDT - 3 months ago

Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona's Pancreas Institute

May 5, 2026, 9:14 AM EDT - 3 months ago

Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab

May 4, 2026, 9:17 AM EDT - 3 months ago

Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026

Apr 29, 2026, 9:00 AM EDT - 4 months ago

Medical University of South Carolina and Revival Healthcare Capital Announce Five-Year Strategic Innovation Partnership

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Alpha Tau Medical Registration statement: Registration filing

Apr 27, 2026, 9:01 AM EDT - 4 months ago

Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies

Apr 23, 2026, 9:02 AM EDT - 4 months ago

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)

Apr 23, 2026, 9:01 AM EDT - 4 months ago

Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial

Mar 31, 2026, 9:15 AM EDT - 5 months ago

Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026

Mar 18, 2026, 10:00 AM EDT - 5 months ago

Alpha Tau Medical Transcript: Sidoti March Small-Cap Virtual Conference

Mar 16, 2026, 10:02 AM EDT - 5 months ago

Alpha Tau to Present at Sidoti March Virtual Small Cap Conference

Mar 10, 2026, 7:00 AM EDT - 5 months ago

Alpha Tau Medical Slides: Investor presentation

Mar 9, 2026, 5:00 PM EDT - 5 months ago

Alpha Tau Medical Annual report: Q4 2025

Mar 9, 2026, 5:00 PM EDT - 5 months ago

Alpha Tau Medical Earnings release: Q4 2025

Mar 9, 2026, 4:02 PM EDT - 5 months ago

Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update

Mar 9, 2026, 7:00 AM EDT - 5 months ago

Alpha Tau Medical Slides: Investor presentation

Feb 24, 2026, 8:51 PM EST - 6 months ago

HekaBio and Alpha Tau Medical Obtain Approval in Japan for Solid Tumor Treatment Alpha DaRT

Feb 24, 2026, 9:00 AM EST - 6 months ago

Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer

Feb 3, 2026, 12:37 PM EST - 7 months ago

Altamirano PLLC Issues Investor Notice on Inspired Healthcare Capital (IHC) Chapter 11 Bankruptcy Filing

Jan 29, 2026, 9:00 AM EST - 7 months ago

Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead

Jan 15, 2026, 4:00 PM EST - 7 months ago

Alpha Tau Medical Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit

Jan 15, 2026, 2:15 PM EST - 7 months ago

Alpha Tau Medical Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 9:00 AM EST - 8 months ago

Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study

Jan 5, 2026, 9:00 AM EST - 8 months ago

Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)

Dec 10, 2025, 11:30 AM EST - 9 months ago

Alpha Tau Medical Transcript: Sidoti's Year End Virtual Investor Conference

Dec 9, 2025, 9:00 AM EST - 9 months ago

Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University

Nov 21, 2025, 7:00 AM EST - 9 months ago

Alpha Tau Medical Slides: Investor presentation

Nov 20, 2025, 4:05 PM EST - 9 months ago

Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 20, 2025, 12:00 AM EST - 9 months ago

Alpha Tau Medical Earnings release: Q3 2025

Nov 11, 2025, 8:30 AM EST - 10 months ago

Alpha Tau to Participate at Jefferies Global Healthcare Conference in London

Oct 21, 2025, 8:30 AM EDT - 10 months ago

Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness

Oct 17, 2025, 10:04 AM EDT - 11 months ago

Altamirano PLLC Issues Notice to Inspired Healthcare Capital (IHC) Investors on Recovery Options

Sep 30, 2025, 12:30 PM EDT - 11 months ago

Alpha Tau Medical Transcript: Lytham Partners Fall 2025 Investor Conference

Sep 2, 2025, 8:30 AM EDT - 1 year ago

Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial

Aug 27, 2025, 8:30 AM EDT - 1 year ago

Alpha Tau to Participate in Five September Investor Conferences

Aug 11, 2025, 4:02 PM EDT - 1 year ago

Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 10, 2025, 6:00 PM EDT - 1 year ago

Alpha Tau Medical Earnings release: Q2 2025

Jul 25, 2025, 9:04 AM EDT - 1 year ago

Revival Healthcare Capital Announces Strategic Partnership to Accelerate External Innovation in Robotics With up to $458 Million Joint Investment With Olympus Into Co-Founded New Company Swan EndoSurgical

Jun 23, 2025, 8:00 AM EDT - 1 year ago

Alpha Tau Medical Registration statement: Registration Filing

May 19, 2025, 4:01 PM EDT - 1 year ago

Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 19, 2025, 4:00 PM EDT - 1 year ago

Alpha Tau Medical Earnings release: Q1 2025

May 12, 2025, 4:01 PM EDT - 1 year ago

Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors

Apr 28, 2025, 9:00 AM EDT - 1 year ago

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

ORMP

Apr 28, 2025, 9:00 AM EDT - 1 year ago

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

ORMP

Apr 2, 2025, 8:30 AM EDT - 1 year ago

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma

Mar 19, 2025, 11:30 AM EDT - 1 year ago

Alpha Tau Medical Transcript: Sidoti Small-Cap Virtual Conference

Mar 12, 2025, 4:02 PM EDT - 1 year ago

Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update

Mar 12, 2025, 4:00 PM EDT - 1 year ago

Alpha Tau Medical Earnings release: Q4 2024

Mar 12, 2025, 4:00 PM EDT - 1 year ago

Alpha Tau Medical Annual report: Q4 2024

Feb 24, 2025, 8:30 AM EST - 1 year ago

Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification

Jan 27, 2025, 9:00 AM EST - 1 year ago

Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day

Jan 27, 2025, 8:00 AM EST - 1 year ago

Alpha Tau Medical Transcript: R&D Day 2025

Jan 27, 2025, 8:00 AM EST - 1 year ago

Alpha Tau Medical Slides: FY 2025

Jan 16, 2025, 12:45 PM EST - 1 year ago

Alpha Tau Medical Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Dec 18, 2024, 8:30 AM EST - 1 year ago

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

Dec 17, 2024, 9:00 AM EST - 1 year ago

Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

Dec 11, 2024, 8:30 AM EST - 1 year ago

Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 6, 2024, 8:30 AM EST - 1 year ago

Alpha Tau to Participate in Ladenburg's Oncology Innovators & Investors Symposium

Nov 18, 2024, 6:00 PM EST - 1 year ago

Alpha Tau Medical Earnings release: Q3 2024

Nov 13, 2024, 8:30 AM EST - 1 year ago

Alpha Tau to Participate in Citi's 2024 Global Healthcare Conference and Piper Sandler's 36th Annual Healthcare Conference

DJTEM Aug. 24 at 7:45 AM

$DRTS At least. Goldie

0 · Reply

Stock_Catcher Aug. 24 at 12:25 AM

Money Monday Watchlist - Daily Expansion $CLOV $RUM $HIVE $HYLN $DRTS

1 · Reply

Jordan3333 Aug. 23 at 10:32 AM

$DRTS Now that we got to $15 the Keytruda IDE announcement can get us beyond the $18, and with the warrant exercise, the price should double

3 · Reply

Jessypenny Aug. 23 at 10:00 AM

$DRTS Getting used to posting this: Another ATH at $15.02 and another highest close at $14.92. Momentum keeps building and I'm Extremely bullish as ever.

0 · Reply

JohnStocksNY Aug. 23 at 7:42 AM

$DRTS I think about Alpha Tau every day.

2 · Reply

Dutchholdem Aug. 22 at 8:10 AM

$DRTS Alpha Tau Medical (DRTS) officer schedules next stock sale under 10b5-1 plan. Yesterday 5k shares at 14.38 approximately it seems as part of predefined plan.

2 · Reply

Watchingnow Aug. 21 at 10:59 PM

$DRTS sold $15 puts expiring today. At 4pm closed below. Hope i get assigned.

0 · Reply

Matilda_CS Aug. 21 at 7:35 PM

2 · Reply

Dutchholdem Aug. 21 at 7:25 PM

$DRTS Raphi auto option executing again like at 14 dollar, or profit takers at 15? I am fine either way, not planning to sell anything

2 · Reply

Matilda_CS Aug. 21 at 6:41 PM

$DRTS with a little push, we could clear 15 by code

2 · Reply

Dutchholdem Aug. 21 at 3:16 PM

$DRTS added at 14.7 to make it a 5k shares total evenly split between normal and retirement account. 5k $ORMP shares as well with a 4-1 split

0 · Reply

SlimyMango Aug. 21 at 2:30 PM

$DRTS

1 · Reply

Jessypenny Aug. 21 at 1:59 PM

$DRTS $15 So Bullish

2 · Reply

Matilda_CS Aug. 21 at 1:37 PM

$DRTS 15 please

1 · Reply

kareem1988 Aug. 21 at 1:12 PM

Quiet week for $DRTS with price action consolidating near the highs. looking to finish the week strong. $15 is right there and would be a nice way to close things out. fundamentals unchanged, still love the setup here.

1 · Reply

Watchingnow Aug. 21 at 12:51 PM

$DRTS can we do $15 today?

2 · Reply

Richland69 Aug. 21 at 12:00 PM

$DRTS Have we ever trended this high? Here’s to hoping someone knows something we don’t!

1 · Reply

mankind1 Aug. 21 at 1:28 AM

$DRTS From my understanding there shouldn't be any new news until November. So not sure what is heating up.

4 · Reply

mankind1 Aug. 21 at 1:15 AM

$DRTS wow. What's cooking?

1 · Reply

Stock_Catcher Aug. 21 at 1:15 AM

Fun Friday Watchlist - Hourly Expansion Up $SLS $DRTS $NUAI $PURR $WETO

1 · Reply

JohnStocksNY Aug. 20 at 7:59 PM

$DRTS There must be something cooking

2 · Reply

Dutchholdem Aug. 20 at 6:59 PM

$DRTS tomorrow salary and DRTS buying day. I actually like the sideway action for my own accumulation possibilities. Though green looks great as well. Catalysts will come, 15 and 20 dollars as well at some pont

1 · Reply

Market Cap	1.35B
Revenue (ttm)	0.00
Net Income (ttm)	-42.63M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.15

Volume	626,200
Avg Vol	676,934
Day's Range	N/A - N/A
Shares Out	90.33M
Stochastic %K	94%
Beta	1.17
Analysts	Strong Sell
Price Target	$13.75